Cosmetic

TrenibotE / BoNT-E

Investigational rapid-onset, short-duration BoNT-E

Duration

未承認

Downtime

未承認

Sessions

未承認 (承認後にラベル準拠)

About This Treatment

TrenibotE is an investigational botulinum toxin serotype E from AbbVie/Allergan Aesthetics. It is designed for rapid onset around 8 hours and short duration around 2-3 weeks, but as of April 2026 the US FDA issued a Complete Response Letter related to manufacturing. It is not approved.

Mechanism of Action

BoNT-E also cleaves SNAP-25 but is expected to have faster onset and shorter duration than BoNT-A. Clinical use should wait for approval.

Indications

Wrinkles / fine linesGeneral indication (see detailed description)

Expected Results

Phase 3 data have been reported for rapid onset and short duration, but as of June 21, 2026 it remains unapproved, so it should be listed as watchlist / not offered.

Clinical Evidence

AbbVie (2026)

FDA Complete Response Letter for TrenibotE BLA. Company / FDA update

Clinical improvement was reported in this study (see original paper for details).

Allergan Aesthetics (2023)

Positive phase 3 topline results of trenibotulinumtoxinE. Company clinical update

Clinical improvement was reported in this study (see original paper for details).

EB-001 investigators (2019)

Safety and efficacy of EB-001, a novel type E botulinum toxin, in glabellar frown lines. Dermatol Surg

Clinical improvement was reported in this study (see original paper for details).

Risks & Side Effects

Not available for routine clinical use before approval. Expected toxin-class risks include bruising, headache, eyelid ptosis, asymmetry and rare swallowing or breathing symptoms.

Interested in this treatment?

Start with an AI skin analysis to check your current skin condition

Get AI Skin Analysis Book Now

Other Treatments

LaserPicoSure ProLearn more LaserFractional LaserLearn more LaserPhotofacial IPL (Stellar M22)Learn more Anti-AgingThermage FLXLearn more